SANUWAVE Health, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
SANUWAVE reported Q2 2026 revenue of $9.7M (down 3% from $10.1M in Q2 2025), with gross margin declining to 76.2% from 78.1%. Operating loss was $0.3M versus $1.4M operating income in Q2 2025; net loss was $0.7M versus $0.6M net income in Q2 2025. System sales fell to 82 units from 116 units YoY, but applicator revenue grew 13% to $7.3M. The company withdrew full-year 2026 guidance, citing market stress from CMS reimbursement changes, customer financial distress, and a secondary market for used equipment cannibalizing new system sales. Adjusted EBITDA declined 63% to $1.2M from $3.2M YoY.
Why this rating
Revenue decline modest in absolute terms ($315K) but paired with profitability collapse (operating swing of $1.7M) and guidance withdrawal signals material market headwinds. Medicare reimbursement risk threatens core 97610 code economics, directly impacting ~$233M market-cap company reliant on wound-care reimbursement.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.